Science Explorer Back to mapMap

Most cited papers from Teva Pharmaceuticals (United States)

What are the most cited papers from Teva Pharmaceuticals (United States)?

The most cited paper from Teva Pharmaceuticals (United States) is "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials" (Mario Castro, James Zangrilli, Michael E. Wechsler et al., 2015), with 1,192 citations. Next come "Fremanezumab for the Preventive Treatment of Chronic Migraine" (824) and "Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study" (646).

Showing 50 of 61 papers. Every paper with more than 84 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Mario Castro, James Zangrilli, Michael E. Wechsler et al. · The Lancet Respiratory Medicine 23 Feb 2015 1,192
2 Fremanezumab for the Preventive Treatment of Chronic Migraine Stephen David Silberstein, David W. Dodick, MARCELO EDUARDO BIGAL et al. · New England Journal of Medicine Open access 24 Nov 2017 824
3 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood Open access 4 Mar 2014 646
4 Animal models of human disease: Challenges in enabling translation Paul McGonigle, Bruce Ruggeri · Biochemical Pharmacology 14 Aug 2013 608
5 Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study David Price, Anna Rigazio, Jonathan D. Campbell et al. · The Lancet Respiratory Medicine Open access 23 Oct 2015 602
6 Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine David W. Dodick, Stephen David Silberstein, MARCELO EDUARDO BIGAL et al. · JAMA Open access 15 May 2018 587
7 Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities Karen Deborah Davis et al. · Nature Reviews Neurology ReviewOpen access 15 Jun 2020 512
8 Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet 16 Aug 2019 445
9 Drug repurposing from the perspective of pharmaceutical companies Yoonjeong Cha, T. Erez, Ian J. Reynolds et al. · British Journal of Pharmacology Open access 29 Mar 2017 440
10 Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels Leif Bjermer, Catherine Lemière, Jorge Fernando Maspero et al. · CHEST Journal Open access 4 Apr 2016 431
11 Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease Huntington Study Group et al. · JAMA Open access 5 Jul 2016 404
12 Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Jonathan Corren, Steven F. Weinstein, Lindsay Janka et al. · CHEST Journal Open access 25 Mar 2016 390
13 Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery Bruce Ruggeri, Faye Camp, Sheila J. Miknyoczki · Biochemical Pharmacology 28 Jun 2013 371
14 Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial Karen Elta Anderson, David A. Stamler, Mat D. Davis et al. · The Lancet Psychiatry 28 Jun 2017 337
15 Anxiety and depression symptoms and migraine: a symptom-based approach research Mário Fernando Prieto Peres, Juliane Prieto Peres Mercante, Patrícia Renovato Tobo et al. · The Journal of Headache and Pain Open access 21 Mar 2017 308
16 Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review Sheela Kolluri, Jianchang Lin, Rachael Liu et al. · The AAPS Journal Open access 4 Jan 2022 303
17 Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study MARCELO EDUARDO BIGAL, David W. Dodick, Alan M. Rapoport et al. · The Lancet Neurology 2 Oct 2015 288
18 Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application Shashank Sharma B. C. Jain, Niketkumar Patel, Mansi K. Shah et al. · Journal of Pharmaceutical Sciences 16 Nov 2016 283
19 Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study MARCELO EDUARDO BIGAL, Lars IH Edvinsson, Alan M. Rapoport et al. · The Lancet Neurology 2 Oct 2015 264
20 Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations Ann Taylor et al. · Pain Open access 7 Apr 2016 215
21 Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea Samuel Frank et al. · JAMA Neurology Open access 10 Jul 2017 213
22 Clinical, humanistic, and economic burden of osteoarthritis among noninstitutionalized adults in the United States Xiaohui Zhao, Drishti Shah, Kavita Gandhi et al. · Osteoarthritis and Cartilage Open access 9 Jul 2019 182
23 Long-term safety, tolerability, and efficacy of fremanezumab in migraine Peter James Goadsby, Stephen David Silberstein, Paul P. Yeung et al. · Neurology Open access 11 Sep 2020 179
24 The First Frontier: Digital Biomarkers for Neurodegenerative Disorders Earl Ray Dorsey, Spyros Papapetropoulos, Mulin Xiong et al. · Digital Biomarkers Open access 4 Jul 2017 171
25 Individual-specific functional connectivity of the amygdala: A substrate for precision psychiatry Chad M. Sylvester et al. · Proceedings of the National Academy of Sciences Open access 3 Feb 2020 150
26 Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS ‐mutant relapsed or refractory myeloid malignancies Gautam M. Borthakur et al. · Cancer Open access 18 Mar 2016 145
27 Research design considerations for chronic pain prevention clinical trials Jennifer S. Gewandter et al. · Pain Open access 16 Apr 2015 145
28 Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002 Sam K. Bouchillon, Brian M Johnson, D. Hoban et al. · International Journal of Antimicrobial Agents 13 Jul 2004 141
29 DNA Triplet Repeat Expansion and Mismatch Repair Ravi R. Iyer, Anna Pluciennik, Марек Напиерала et al. · Annual Review of Biochemistry ReviewOpen access 12 Jan 2015 134
30 The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study Stephen D. Silberstein, Joshua M. Cohen, Michael J. Seminerio et al. · The Journal of Headache and Pain Open access 21 Sep 2020 132
31 Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization Srushti M. Tambe, Divya D. Jain, Saikishore Meruva et al. · Pharmaceutics Open access 16 Oct 2022 127
32 Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils Guy Brusselle, Matthew Germinaro, Sivan Weiss et al. · Pulmonary Pharmacology & Therapeutics Open access 31 Jan 2017 126
33 Digital Health Technology in Asthma: A Comprehensive Scoping Review Giselle S Mosnaim, GUILHERME G SAFIOTI, Randall W. Brown et al. · The Journal of Allergy and Clinical Immunology In Practice Open access 27 Feb 2021 120
34 Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients Fumihiko Sakai, Norihiro Suzuki, Byung‐Kun Kim et al. · Headache The Journal of Head and Face Pain Open access Jul 2021 116
35 Selection of optimal reference genes for normalization in quantitative RT-PCR Inna Chervoneva, Yanyan Li, Stephanie M. Schulz et al. · BMC Bioinformatics Open access 14 May 2010 115
36 Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors Thelma S. Angeles, Robert L. Hudkins · Expert Opinion on Drug Discovery 5 Oct 2016 114
37 Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study Ralf Reilmann et al. · The Lancet Neurology 120 authors 15 Dec 2018 112
38 Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System Nádia Araci Bou‐Chacra, Katherine Jasmine Curo Melo, Ivan Andrés Cordova Morales et al. · The AAPS Journal Open access 17 May 2017 110
39 Comparison of the size and morphology of UHMWPE wear debris produced by a hip joint simulator under serum and water lubricated conditions A. Wang, Aaron Essner, C Stark et al. · Biomaterials 1996 110
40 Application of Melt Granulation Technology to Enhance Tabletting Properties of Poorly Compactible High-Dose Drugs Jay P. Lakshman, James Kowalski, Madhav Vasanthavada et al. · Journal of Pharmaceutical Sciences 3 Dec 2010 106
41 Therapeutic antibodies against CGRP or its receptor MARCELO EDUARDO BIGAL, Sarah J. Walter, Alan M. Rapoport · British Journal of Clinical Pharmacology Open access 23 Jan 2015 106
42 Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease Daniel O. Claassen, Benjamin Carroll, Lisa M. De Boer et al. · Journal of Clinical Movement Disorders Open access 15 Feb 2017 105
43 Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims Benjamin J. Chastek, MerriKay A. Oleen-Burkey, Maria V. Lopez-Bresnahan · Journal of Medical Economics Open access Oct 2010 105
44 Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients Fumihiko Sakai, Norihiro Suzuki, Byung‐Kun Kim et al. · Headache The Journal of Head and Face Pain Open access Jul 2021 103
45 Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine Stephen David Silberstein, Lulu Lee, Kavita Gandhi et al. · Headache The Journal of Head and Face Pain 30 Oct 2018 103
46 Inspiring process innovation via an improved green manufacturing metric: iGAL Frank Roschangar et al. · Green Chemistry 2018 103
47 2 Discovery of Cep-1347/Kt-7515, an Inhibitor of the Jnk/Sapk Pathway for the Treatment of Neurodegenerative Diseases Michael S. Saporito, Robert L. Hudkins, Anna Coco Maroney · Progress in medicinal chemistry Book chapter 2002 98
48 NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019 William G. Wierda et al. · Journal of the National Comprehensive Cancer Network 2019 95
49 Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations Maciej Ga̧sior, Mary Lou Bond, Richard I. Malamut · Postgraduate Medicine Open access 13 Nov 2015 93
50 Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK) Gregory R. Ott et al. · Journal of Medicinal Chemistry Open access 15 Aug 2016 92

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.